Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy

spinal muscular atrophy
Until the FDA’s approval of Zolgensma in May 2019, Biogen’s Spinraza was the only approved treatment for SMA patients. Credit: Chinnapong/Shutterstock.